Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2017

View Archived Issues

Cydan raises funds to support development of drugs for rare genetic diseases

Arbutus Biopharma and Gritstone Oncology enter LNP technology licensing agreement

First patient enrolled in phase I study of MABp1 with Onivyde and 5-fluorouracil/folinic acid

Dynavax Technologies doses first patient in phase Ib study of DV-281 in NSCLC

Anetumab ravtansine not superior to vinorelbine in malignant pleural mesothelioma trial

Health Canada gives priority review status to ProMetic's NDS for Ryplazim

Lycera starts phase IIa portion of ARGON study of LYC-55716

Arcturus Therapeutics and Janssen Pharmaceuticals enter strategic collaboration for RNA medicines

ABBV-399 in combination with erlotinib shows promise for the treatment of NSCLC

Q BioMed develops new candidate for pediatric nonverbal disorder

Lorlatinib active in ALK+ non-small cell lung cancer

AOBiome reports positive results from phase IIb study of AOB candidate for acne

Tyme Technologies reports additional analyses from trial of SM-88 in metastatic cancer

Corbus Pharmaceuticals reports positive results from phase II study of anabasum in dermatomyositis

Takeda discovers novel monoglyceride lipase inhibitors

Katholieke Universiteit Leuven, Janssen discover new dengue virus replication inhibitors

Novel mGlu5 receptor antagonists identified at Hua Medicine

Institut Curie and IRPF to collaborate on immune-oncology projects

Innovatives Molecules discovers new antiviral agents

Novel nanovaccines created at the University of Texas

EMA grants orphan drug designation to G-100 for the treatment of follicular non-Hodgkin's lymphoma

FDA awards orphan drug status to Pluristem's PLX-R18 for ARS

Celgene discontinues phase III trials of GED-0301 in Crohn's disease

Millennium Pharmaceuticals recruiting subjects in phase I/IIa trial of TAK-573 in MM

Phase I trial of 225Ac-J591 in patients with metastatic castration-resistant prostate cancer

Three miRNAs validated for pancreatic neuroendocrine tumor prognostic significance

Archivel Farma's TB vaccine reviewed at WHO meeting